$10 Billion Deal, page-165

From the Trial
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372075

Secondary outcome [1]
Evauate if 12 weeks of BIT225 treatment in addition to cART: Atripla will impact levels of sCD163, a primary biomarker of monocyte immune activation.
Timepoint [1]
Blood samples for detection of immune marker sCD163 will be collected from all participants in the BIT225 200mg/placebo cohort at Screening, and then at Day 7, 10, 14, 17, 21, and at Weeks 4, 6, 9 12 and follow-up Weeks 16, and 24 and will be determined by ELISA.

"there was a significant reduction in the level of the macrophage activation marker sCD163 in the BIT225-treated population by the end of the treatment period. Higher levels of sCD163 are linked with worse clinical outcomes in patients. This reduction of sCD163 by BIT225 may provide additional clinical benefit in these patients."

This result is not surprising as sCD163 is likely to go down for those with less than 1 year HIV infection and who have never had any treatment like those individuals in this BIT255 trial.

https://academic.oup.com/jid/article/204/1/154/2192372

"In individuals with early HIV infection (≤1 year in duration), effective ART resulted in decreased sCD163 levels that were comparable to levels in HIV-seronegative individuals."